Before launching into a discussion of what firms need to consider when identifying “best practices” to get a biosimilar up and running in a new market, Mylan’s global commercial head for biologics and insulin gave a quick history lesson about how far the field has come in a keynote address at the 14th Biosimilars Summit, held January 22-23, 2019, in Alexandria, Virginia.
Before launching into a discussion of what firms need to consider when considering “best practices” to get a biosimilar up and running in a new market, Mylan’s global commercial head for biologics and insulin gave a quick history lesson about how far the field has come in a keynote address at the 14th Biosimilars Summit, held January 22-23, 2019, in Alexandria, Virginia.
However, despite the advances that have been made—such as getting past issues of CMS coding and the Supreme Court ruling that changed the interpretation of the 180-day notice manufacturers have to give—it is still a turbulent, a constantly changing field, and there is no one-size-fits-all strategy, said Chrys Kokino. Price and competition pressures are real, especially in Europe, where prices are falling.
“If you know one country in Europe, you know one country,” said Kokino.
Mylan, which focuses on partnership agreements, launched Hulio, the adalimumab biosimilar referencing Humira, with Fujifilm Kyowa Kirin Biologics last year after receiving approval from the European Commission. Hulio is not the only biosimiliar adalimumab on the market in Europe. AbbVie, Humira’s maker, has already lost patent exclusivity in Europe, allowing competitors to enter.
Although approvals are centrally managed in Europe, individual governments negotiate reimbursement. Kokino said there are complications to every market entry, in terms of trying to provide access and affordability to patients while appeasing concerns from stakeholders, shareholders, and top executives.
“There’s a tremendous amount of investment that has to take place,” he said.
Collectively, those in the biosimilar industry must decide what their ultimate objective is, he said. Mylan has a portfolio of 20 biosimilars in 5 disease categories and has the objective of building a sustainable business over time, he said. But Kokino noted that there are at least 4 areas to consider when thinking about entering a biosimilar market: partnerships, market dynamics, research and development, and the commercial launch.
Not every manufacturer is deciding to stay the course, he noted, pointing to, as just one example, Merck deciding to end its partnership with Samsung Bioepsis for a follow-on to Lantus. In addition, Pfizer decided to drop 5 preclinical programs. Mylan, however, is continuing with a decision to produce insulin products at a factory in Malaysia owned by its partner, Biocon.*
To stay in the market, though, means putting patients at the center in terms of access and affordability. He said it requires a “very fine balance” of multiple stakeholder objectives. In addition, he said the entry of new competition means that views on existing relationships with stakeholders may change.
Kokino stressed that he wasn’t passing a judgement on which was the better strategy—to stay in the market, trim, or sit on the sidelines and wait until, as he put it, “until the dust settles.”
While it is his hope that biosimilars become mainstream, it will require a massive educational effort. To that end, the industry has to make sure they are represented at medical and scientific meetings as well as in peer-reviewed journals, editorials, and review articles, he said.
*This story has been updated to reflect that the factory referenced is an existing facility of Mylan's partner, Biocon.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market
April 25th 2025Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).